The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments

Journal of Pharmacological and Toxicological Methods

Volumn 57, Issue 2, 2008, Pages 114-130

  Ravenstijn, Paulien G M ^a   Merlini, Mario ^a   Hameetman, Marjolijn ^a   Murray, Tracey K ^b   Ward, Mark A ^b   Lewis, Hywel ^b   Ball, Gareth ^b   Mottart, Cathy ^c   de Ville de Goyet, Christine ^c   Lemarchand, Thomas ^c   van Belle, Kristel ^c   O'Neill, Michael J ^b   Danhof, Meindert ^a   de Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly Benelux   (Belgium)

Author keywords

Blood brain barrier; Methods; Microdialysis; Neurotoxicity; Parkinson's disease; Rat; Rotational behaviour; Rotenone; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE; FLUORESCEIN SODIUM; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; CELL AGGREGATION; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC ACTIVITY; HEART; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY; LIVER; LUNG; MALE; MEDIAL FOREBRAIN BUNDLE; MICRODIALYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORGAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PERMEABILITY; RAT; SPLEEN; STOMACH;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUORESCEIN; FLUORESCENT DYES; INFUSION PUMPS, IMPLANTABLE; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NEUROTOXINS; PARKINSON DISEASE, SECONDARY; RATS; RATS, INBRED LEW; ROTENONE;

RATTUS;

EID: 40649108829     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.10.003     Document Type: Article

References (53)

1. Alam M., Mayerhofer A., and Schmidt W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-Dopa. Behavioural Brain Research 151 1-2 (2004) 117-124
2. Alexander G.M., Schwartzman R.J., Grothusen J.R., and Gordon S.W. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP Parkinsonian monkeys. Neurology 44 8 (1994) 1491-1499
3. Alexander G.M., Schwartzman R.J., Grothusen J.R., and Gordon S.W. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP Parkinsonian monkeys. Neurology 44 8 (1994) 1491-1499
4. Antkiewicz-Michaluk L., Wardas J., Michaluk J., Romaska I., Bojarski A., and Vetulani J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. International Journal of Neuropsychopharmacology, 7 2 (2004) 155-163
5. Bahnemann R., Jacobs M., Karbe E., Kaufmann W., Morawietz G., Nolte T., et al. RITA-registry of industrial toxicology animal-data-guides for organ sampling and trimming procedures in rats. Experimental and Toxicologic Pathology 47 4 (1995) 247-266
6. Beal M.F. Experimental models of Parkinson's disease. Nature Reviews. Neuroscience 2 5 (2001) 325-334
7. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 4 (2002) 308-318
8. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 3 12 (2000) 1301-1306
9. Bonuccelli U., and Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67 7 Suppl 2 (2006) S30-S38
10. Boorman G.A., Eustis S.L., Elwell M.R., Montgomery C.A., and MacKenzie W.F. Pathology of the fisher rat-reference and atlas (1990)
11. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. Journal of the National Cancer Institute 92 16 (2000) 1295-1302
12. Carvey P.M., Zhao C.H., Hendey B., Lum H., Trachtenberg J., Desai B.S., et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. European Journal of Neuroscience 22 5 (2005) 1158-1168
13. Chan P.L., Nutt J.G., and Holford N.H. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. Journal of Pharmacokinetics and Pharmacodynamics 32 3-4 (2005) 307-331
14. Chen S., and Le W. Neuroprotective therapy in Parkinson disease. American Journal of Therapeutics 13 5 (2006) 445-457
15. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 15 6 (2002) 991-998
16. Cotran R.S., Kumar V., and Collins T. Cellular pathology II: Adaptations, intracellular accumulations, and cell aging. Robbins' pathologic basis of disease (1999), WB Sauners company 31-49
17. Dauer W., and Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 39 6 (2003) 889-909
18. de Boer A.G., van der Sandt I.C., and Gaillard P.J. The role of drug transporters at the blood-brain barrier. Annual Review of Pharmacology and Toxicology 43 (2003) 629-656
19. de Lange E.C., Danhof M., de Boer A.G., and Breimer D.D. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Research Brain Research Reviews 25 1 (1997) 27-49
20. de Lange E.C., Marchand S., van den Berg D.J., van der Sandt I.C., de Boer A.G., Delon A., et al. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. European Journal of Pharmaceutical Sciences 12 2 (2000) 85-93
21. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Experimental Neurology 187 2 (2004) 418-429
22. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proceedings of the National Academy of Sciences, United States of America 102 9 (2005) 3413-3418
23. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews.Cancer 2 1 (2002) 48-58
24. Hammarlund-Udenaes M., Paalzow L.K., and de Lange E.C. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharmaceutical Research 14 2 (1997) 128-134
25. Harder S., and Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clinical Pharmacology and Therapeutics 64 2 (1998) 183-191
26. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. Journal of Neurochemistry 84 3 (2003) 491-502
27. Kortekaas R., Leenders K.L., van Oostrom J.C.H., Vaalburg W., Bart J., Willemsen A.T.M., et al. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology 57 (2005) 176-179
28. Lapointe N., St Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB Journal 18 6 (2004) 717-719
29. Loscher W., and Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2 1 (2005) 86-98
30. Mercuri N.B., and Bernardi G. The 'magic' of l-Dopa: Why is it the gold standard Parkinson's disease therapy?. Trends in Pharmacological Sciences 26 7 (2005) 341-344
31. Moghaddam B., and Bunney B.S. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. Journal of Neurochemistry 53 2 (1989) 652-654
32. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., et al. LY503430, a novel {alpha}-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics 306 2 (2003) 752-762
33. O'Neill M.J., Murray T.K., Whalley K., Ward M.A., Hicks C.A., Woodhouse S., et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. European Jouranl of Pharmacology 486 2 (2004) 163-174
34. Palmer N. Bones and Joints. Pathology of domestic animals: (1993), Academic Press Inc. 1-181
35. Paxinos G., Watson C., Pennisi M., and Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. Journal of Neuroscience Methods 13 2 (1985) 139-143
36. Phinney A.L., Andringa G., Bol J.G., Wolters E.C., van Muiswinkel F.L., van Dam A.M., et al. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Related Disorder 12 4 (2006) 228-238
37. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience 11 5 (1999) 1554-1566
38. Sachs C., and Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochemical Pharmacology 24 1 (1975) 1-8
39. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Research 1049 2 (2005) 147-155
40. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 2 (1994) 401-415
41. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: Molecules to medicine. Journal of Clinical Investigation 116 7 (2006) 1744-1754
42. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Advanced Drug Delivery Reviews 36 2-3 (1999) 179-194
43. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 97 11 (1996) 2517-2524
44. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell and Tissue Research 318 (2004) 215-224
45. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology 179 1 (2003) 9-16
46. Sindhu K.M., Saravanan K.S., and Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Research 1051 1-2 (2005) 25-34
47. Sousa S.C., and Castilho R.F. Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death. Antioxidants and Redox Signalling 7 9-10 (2005) 1110-1116
48. Sousa S.C., Maciel E.N., Vercesi A.E., and Castilho R.F. Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone. FEBS Letters 543 1-3 (2003) 179-183
49. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: Understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell and Tissue Research 318 (2004) 225-241
50. van der Sandt I.C., Smolders R., Nabulsi L., Zuideveld K.P., de Boer A.G., and Breimer D.D. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. European Journal of Pharmaceutical Sciences 14 1 (2001) 81-86
51. Vautier S., Lacomblez L., Chacun H., Picard V., Gimenez F., Farinotti R., et al. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. European Journal of Pharmaceutical Sciences 27 2-3 (2006) 167-174
52. Visanji N.P., O'Neill M.J., and Duty S. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51 3 (2006) 506-516
53. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., DiCarlo C.D., et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. Journal of Comparative Neurology 478 4 (2004) 418-426